AstraZeneca defends diabetes medications in triple lawsuits
The UK pharmaceutical company filed three lawsuits against Sun Pharma | Sun’s abbreviated new drug application for generic versions of diabetes medications sparks fightback.
AstraZeneca has filed three lawsuits against Sun Pharmaceuticals for alleged infringement related to its diabetes medication.
The suits, filed in the US District Court for the District of Delaware, claimed that Sun violated patent laws by filing an abbreviated new drug application to the US Food and Drug Administration (FDA).
The application sought approval to market generic versions of AstraZeneca’s diabetes medications, Farxiga, Qtern, and Xigduo XR.
The three complaints, filed on Monday 4, alleged the targeted generic drug infringes on AstraZeneca's US patent number 6,515,117.
The ’117 patent is set to expire on October 4, 2025.
The Anglo-Swedish company markets the three in the US primarily for the treatment of type 2 diabetes.
Sun, an Indian corporation, is accused of formulating, manufacturing, packaging, and marketing generic drug products that allegedly infringe on AstraZeneca's patented technology.
AstraZeneca also argued that Sun's actions, if left unchecked, will result in irreparable harm to the company.
AstraZeneca sought various forms of relief from the court, including judgments declaring Sun's infringement, an injunction against manufacturing and selling the allegedly infringing products, and damages for any harm caused.
Additionally, AstraZeneca requested the court to declare this case an exceptional one and award the company costs, expenses, and attorney fees.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox.
